Although no cause of death or further details were given, the news comes months after Lynch announced he had been living with ...

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on ...

Bernstein has upgraded Beam Therapeutics (BEAM) to outperform, citing upcoming data on the company’s drug candidate for AATD.

Oppenheimer initiated coverage of Korro Bio (KRRO) with an Outperform rating and $155 price target The company’s Opera platform enables ...

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

Taiwan Coast Guard says ship that allegedly cut cable crewed by Chinese ...

Intellia Therapeutics (NTLA) announced a strategic reorganization focused on key value drivers. The pipeline prioritization is intended to ...